Airlines Set to Save Millions as Passengers Slim Down with Weight-Loss Drugs

A recent study has revealed that airlines in the United States could potentially save up to $580 million each year, thanks to the increasing usage of weight-loss drugs by travelers. According to Sheila Kahyaoglu, an equity analyst at Jefferies and author of the study, the top four airlines in the country – American Airlines, Delta Air Lines, Southwest Airlines, and United Airlines – will benefit from lower fuel costs due to the decreased weight of their passengers.

The study, which was published in the New York Times, highlights how airlines have always been conscious about reducing aircraft weight to save on fuel costs. However, the weight of passengers was not something they could control until now. With the rising popularity of weight-loss drugs such as Ozempic and Wegovy, airlines can now expect to see significant savings in their operational costs.

The demand for these weight-loss drugs has been on the rise in the US, with Novo Nordisk – the company behind Wegovy – also working on an oral version of the drug to make it more convenient for customers. This trend is expected to continue, as more and more people are looking for ways to lose weight and improve their health.

In an interview with Fox Business, Novo Nordisk executive Dave Moore shared that the company received FDA approval for the oral GLP-1 drug in December 2025 and has already launched it in the US market this month. Moore also mentioned that the availability of the pill has generated a lot of excitement and interest among customers who were previously hesitant to try the injectable version.

To make these weight-loss drugs more accessible and affordable, Costco has partnered with Novo Nordisk to offer them at a lower price to its members. The cost of the oral semaglutide pill is significantly lower than the injectable version, with insured customers paying around $25 per month and uninsured customers paying $149 per month.

This rise in the usage of weight-loss drugs not only benefits airlines but also highlights the growing concern about obesity and the need for effective solutions. With more companies and individuals focusing on weight management, the demand for these drugs is expected to continue to grow. It remains to be seen how this trend will evolve in the future and what impact it will have on the airline industry and overall health and wellness.